Also known as: BPH, benign prostatic hypertrophy, prostatic enlargement, LUTS, lower urinary tract symptoms
Overview
Histologic diagnosis of hyperplasia of prostatic stromal and epithelial cells, typically producing transitional zone enlargement and bladder outlet obstruction with lower urinary tract symptoms (LUTS).
Epidemiology
Histologic BPH present in ~50% of men over 50 and ~80% over 80; ~25-30% experience moderate-to-severe LUTS.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Benign Prostatic Hyperplasia (BPH) outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Age-related hormonal changes (rising estrogen-to-testosterone ratio, continued local DHT production via 5-alpha-reductase) drive nodular hyperplasia in the transitional zone, compressing the prostatic urethra. Alpha-1-adrenergic tone in prostatic smooth muscle contributes to dynamic obstruction (vs static obstruction from gland size).
Reduces risk of acute urinary retention and need for surgery
Reduces PSA by ~50% — multiply measured PSA by 2 for cancer screening interpretation
Side effects: sexual dysfunction (decreased libido, ED, ejaculatory disorders), gynecomastia
Combination therapy
Alpha-blocker + 5-ARI (e.g., tamsulosin + dutasteride) — superior to monotherapy for moderate-to-severe symptoms with prostate enlargement (MTOPS, CombAT trials)
Use for at least 1 year for full benefit
Other pharmacologic options
PDE5 inhibitor — tadalafil 5 mg daily — useful when ED coexists
Anticholinergics or beta-3 agonists (mirabegron) — if overactive bladder symptoms predominate; caution if elevated PVR
Endoscopic: transurethral resection of the prostate (TURP) — historical gold standard; transurethral incision of prostate (TUIP) for small glands
Laser enucleation (HoLEP, ThuLEP) — for very large prostates
Open or robotic simple prostatectomy — for very large (>80-100 g) prostates
Complications
Acute urinary retention (AUR) — sudden inability to void, painful distended bladder; treat with catheter, alpha-blocker; trial of void after 3-7 days
Recurrent UTI
Bladder stones, hematuria
Bladder decompensation, hydronephrosis, postrenal AKI
Surgical complications: bleeding, retrograde ejaculation (~70% after TURP), urinary incontinence, urethral stricture, TUR syndrome (hyponatremia from monopolar irrigation)
PANCE pearls
5-alpha reductase inhibitors reduce serum PSA by ~50%; double the measured PSA when screening men on finasteride/dutasteride.
Alpha-blockers can cause intraoperative floppy iris syndrome — alert ophthalmology before cataract surgery; effect can persist for weeks after discontinuation.
Acute urinary retention is treated with urethral catheterization; do NOT rapidly decompress >1 L (can cause hematuria, hypotension) — use intermittent clamping.
Avoid anticholinergics, opioids, decongestants, and antihistamines in BPH patients — can precipitate retention.
Daily tadalafil 5 mg is approved for both BPH and ED — useful when both conditions coexist.
Combination therapy (alpha-blocker + 5-ARI) is best for men with large prostates and bothersome symptoms; expect at least 6-12 months for full effect of 5-ARI.
BPH ≠ prostate cancer — discuss separate cancer screening based on patient preferences and risk.
References
AUA 2023 — Management of Benign Prostatic Hyperplasia: AUA Guideline (Sandhu et al., J Urol 2023)
MTOPS — The Long-term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of BPH (McConnell et al., NEJM 2003)
CombAT — Dutasteride plus Tamsulosin Combination Treatment in Men with BPH (Roehrborn et al., Eur Urol 2010)
Practice Reproductive questions on FirstPassPA
Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.